PHILIP SAMUEL SCHEIN
Medical Practice in Delaware

5824664, Oct 20, 1998

Mar 26, 1993

8/037633

Philip S. Schein - Bryn Mawr PA
Thea Kalebic - Bethesda MD

U.S. Bioscience, Inc. - West Conshohocken PA
National Institutes of Health, The National Cancer Institute - Rockville MD

A01N 5710, A01N 5700, A61K 3166, A61K 3113

514143

Chronic HIV infection is treated by administering to a subject an organic thiophosphate alone or in combination with another anti-HIV or anti-AIDS drug. The organic thiophosphate is preferably WR 151327, a compound with antioxidant and free radical scavenging activities, or a functional derivative or analogue thereof. WR 151327 suppresses induction of HIV expression in chronically infected cells mediated by cytokines such as TNF. alpha. and GM-CSF. Pharmaceutical compositions comprising at least one organic thiophosphate in combination with one or more anti-HIV or anti-AIDS drugs are also disclosed.

6051563, Apr 18, 2000

Feb 12, 1997

8/798840

Martin Stogniew - Blue Bell PA
Philip S. Schein - Bryn Mawr PA

U.S. Bioscience, Inc. - West Conshohocken PA

A61K 3166

514114

The present invention provides methods of administering aminoalkyl phosphorothioate and/or aminoalkyl thiol compounds to patients in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.

6218377, Apr 17, 2001

Jun 5, 2000

9/586753

Martin Stogniew - Blue Bell PA
Philip S. Schein - Bryn Mawr PA

MedImmune Oncology Inc. - West Conshohocken PA

A01N 5700

514114

The present invention provides methods of administering aminoalkyl phosphorothioate and/or aminoalkyl thiol compounds to patients in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.

4720543, Jan 19, 1988

Jun 6, 1985

6/742045

Eugene McPherson - Forestville MD
Philip S. Schein - Bryn Mawr PA

Georgetown University - Washington DC

C07D48714, A61K 2100, A61K 3140

536 181

This invention discloses 1a- and 7-substituted derivatives of mitosanes containing thiocarbamoyl and glycosyl residues. The compounds possess antibacterial and antitumor activity, with a concomitant reduction in bone marrow toxicity as compared to the parent compounds.

5091523, Feb 25, 1992

Dec 3, 1990

7/620853

Abdolhossen Talebian - Herndon VA
Dianna Green - Falls Church VA
Charles Hammer - Washington DC
Philip Schein - Bryn Mawr PA
Alem Ghiorghis - Washington DC
Robert R. Clarke - Bethesda MD

Georgetown University - Washington DC

A61K 3140, A61K 2100, C07D48714

536 173

The invention relates to certain derivatives of mitomycins A and C and the use thereof to treat bacterial infections and to supress the growth of cancer cells. The invention also relates to processes for the preparation of the mitomycin derivatives of the invention.

5804571, Sep 8, 1998

Jun 7, 1995

8/486625

Philip S. Schein - Bryn Mawr PA

U.S. Bioscience - Blue Bell PA

A61K 3170, A61K 3166

514114

S-. omega. (. omega. -aminoalkylamino)alkyl dihydrogen phosphorothioates or pharmaceutically acceptable derivatives thereof are useful in protecting a patient undergoing AZT treatment for AIDS and AIDS-related complex from the harmful side effects or reactions and toxicity of the AZT.

4946954, Aug 7, 1990

Jan 26, 1989

7/301773

Abdolhossen Talebian - Herndon VA
Dianna C. Green - Falls Church VA
Philip S. Schein - Bryn Mawr PA

Georgetown University - Washington DC

C07H 1500, C07H 2300

536121

Platinum compounds useful in the treatment of cancer are disclosed. Compositions containing these compounds and methods of using the same are also discussed. Compounds having the formula ##STR1## wherein n is 0 or 1 and when n is 1 R. sub. 1 is H or C. sub. 1 -C. sub. 4 alkyl, R is non-substituted higher alkyl or mono or disaccharide or a derivative of a mono or disaccharide, when n is O, R. sub. 1 is H or C. sub. 1 -C. sub. 4 alkyl, R is H, halogen, non-substituted C. sub. 1 -. sub. 20 alkyl, aryl, arlalkyloxy, mono or disaccharide, or a derivative of a mono or disaccharide, and R. sub. 2 and R. sub. 3 are selected from the group consisting of hydrogen, C. sub. 1. sup. -4 alkyl or R. sub. 2 and R. sub. 3 or R. sub. 2 and R. sub. 3 together are linked to adjacent carbon atoms on a four, five or six membered ring structure, or R. sub. 2 and R. sub.

6127351, Oct 3, 2000

Feb 10, 1998

9/021139

Martin Stogniew - Blue Bell PA
Philip S. Schein - Bryn Mawr PA

MedImmune Oncology Inc. - West Conshohocken PA

A61K 3166

514114

The present invention provides methods of administering aminoalkyl phosphorothioate and/or aminoalkyl thiol compounds to patients in a manner that significantly reduces or decreases the adverse or undesirable side-effects of the compounds as compared with conventional intravenous administration.

4895935, Jan 23, 1990

Jan 14, 1988

7/143762

Abdolhossen Talebian - Herndon VA
Dianna C. Green - Falls Church VA
Charles F. Hammer - Washington DC
Philip S. Schein - Bryn Mawr PA

Georgetown University - Washington DC

C07H 1500, C07H 2300

536 171

Platinum compounds of the formulae: ##STR1## are disclosed. Compositions containing these compounds and methods of using the same in the treatment of tumors are also discussed.